p53 and XRCC1 protein expression were evaluated in 54 samples of non-small cell lung cancer.
Patients and methods
The immunohistochemical method was used for detection of the monitored proteins. Tissue samples were divided according to histopathological tumor type. The results were then compared with basic clinical and histopathological parameters (histopathological type, nuclear grade and TNM tumor stage IA, IB).
Results
Statistically significant correlations were found between histopathological type and p53 expression, since P <0.05 (P = 0.015). Comparing p53 expression with grade resulted in a strong positive correlation (P <0.0396, R2 = 0.9223). The percentage of p53-positive tumors progressively increased from 0% in grade 1 to 75% in grade 4. No correlation was found between p53 expression and tumor stage. In case of XRCC1, the highest level was found in squamous cell lung carcinoma, where 71% of samples was positive. In case of large cell carcinoma samples, it was 67%, and in adenocarcinoma 52% of samples showed XRCC1 immunoreactivity. No statistically significant correlation was found between histopathological type, grade or early stage (IA, IB) of non-small cell lung cancer and expression of XRCC1 protein profile without neoadjuvant therapy.
Conclusions
We found a statistically significant correlation between p53 expression and histopathological tumor type. It is possible that stabilized p53 protein plays an important role in the development of squamous and large cell carcinoma. Our findings also suggest that p53 expression cumulates with the dedifferentiation of cancer cells. It is possible that the expression of XRCC1 is not fixed and could be changed by the status of cancer cells and in relation to therapy. Relevant data about pre- versus post-chemotherapy and XRCC1 expression are needed to evaluate the influence of XRCC1 on drug resistance. Free full text available at www.tumorionline.it
SzczukaI., Roszkowski-SlizK.: Rak pluca w Polsce w latach 1970–2004.Pneumonol Alergol Pol, 76: 19–28, 2008.
2.
HinsonK.F., MillerA.B., TallR.: An assessment of the World Health Organization classification of the histologic typing of lung tumors applied to biopsy and resected material.Cancer, 35: 399–405, 1975.
3.
HanahanD., WeinbergerR.A.: The hallmarks of cancer.Cell, 100: 57–70, 2000.
4.
MaoL., HrubanR.H., TockmanM., SidranskyD.: Detection of oncogene mutations in sputum precedes diagnosis of lung cancer.Cancer Res, 54: 1634–1637, 1994.
5.
BosariS., VialeG.: The clinical significance of p53 aberrations in human tumours.Virchows Arch, 427: 229–241, 1995.
6.
HarrisS.L., LevineA.J.: The p53 pathway: positive and negative feedback loops.Oncogene, 24: 2899–2908, 2005.
7.
SigalA., RotterV.: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.Cancer Res, 60: 6788–6793, 2000.
8.
El-HizawiS., LagowskiJ.P., Kulesz-MartinM., AlborA.: Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.Cancer Res, 62: 3264–3270, 2002.
9.
ShenM.R., JonesI.M., MohrenweiserH.: Nonconservative amino acid substitution variants exit at polymorphic frequency in DNA repair genes in healthy humans.Cancer Res, 58: 604–608, 1998.
10.
WangY., SpitzM.R., ZhuY.: From genotype to phenotype: correlation XRCC1 polymorphisms with mutagen transporter.DNA Repair (Amst), 2: 901–908, 2003.
11.
ThompsonL.H., WestM.G.: XRCC1 keeps DNA from getting stranded.Mutat Res, 459: 1–18, 2000.
12.
BrambillaE., TravisW.D., ColbyT.V., CorrinB., ShimosatoY.: The new World Health Organization Classification of lung tumours.Eur Respir J, 18: 1059–1068, 2001.
13.
MountainC.F.: Revisions in the international system for staging lung cancer.Chest, 111: 1710–1717, 1997.
14.
MitsudomiT., OyamaT., NishidaK., OgamiA., OsakiT., NakanishiR., SugioK., YasumotoK., SugimachiK.: P53 nuclear immunostaining and gene mutations in non-small cell lung cancer and their effect on patients' survival.Ann Oncol, 6: 9–13, 1995.
15.
BodnerS.M., MinnaJ.D., JensenS.M., D'AmicoD., CarboneD., MitsudomiT., FedorkoJ., BuchhagenD.L., NauM.M., GazdarA.F.: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.Oncogene, 7: 743–749, 1992.
LaiR.S., WangJ.S., HsuH.K., ChangH.C., LinC.H., LinM.H.: Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer.Jpn J Clin Oncol, 32: 393–397, 2002.
18.
OhmuraY., AoeM., AndouA., ShimizuN.: Telomerase activity and bcl-2 expression in non-small cell lung cancer.Clin Cancer Res, 6: 2980–2987, 2000.
19.
HainautP., PfeiferG.P.: Patterns of p53 T G transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke.Carcinogenesis, 22: 367–374, 2001.
20.
PiyathilakeJCh, FrostA.R., ManneU., WeisH., HeimburgerD.C., GrizzleW.E.: Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers.Chest, 123: 181–186, 2003.
21.
DworakowskaD., GozdzS., JassemE., BadzioA., KobierskaG., UrbaniakA., SkokowskiJ., DampsI., JassemJ.: Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer.Lung Cancer, 35: 35–41, 2002.
22.
PollánM., VarelaG., TorresA., de la TorreM., LudeñaM.D., OrtegaM.D., PacJ., FreixenetJ., GómezG., SebastiánF., DíezM., ArrabalR., CanalísE., García-TiradoJ., ArnedilloA., RivasJ.J., MinguellaJ., GómezA., GarcíaM., AragonésN., Pérez-GómezB., López-AbenteG., González-SarmientoR., RojasJ.M.: Clinical value of p53, c-erb-B2, CEA and CA 125 regarding relapse, metastasis and death in resectable non-small cell lung cancer.Int J Cancer Res, 10: 781–790, 2003.
23.
PorebskaI., KosackaM., WyrodekE., JankowskaR.: Expression of p53, bcl-2 and nm23 proteins in squamous cell lung cancer.Pneumonol Alergol Pol, 77: 131–137, 2009.
24.
DemarchiL.M., ReisM.M., PalominoS.A., FarhatC., TakagakiT.Y., BeyrutiR., SaldivaP.H., CapelozziV.L.: Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung.Mod Pathol, 13: 511–520, 2000.
25.
CarvalhoP.E., AntonangeloL., BernardiF.D., LeaoL.E., RodriguesO.R., CapelozziV.L.: Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas.Jpn J Clin Oncol, 30: 478–486, 2000.
26.
Massoni NetoL.M., BianchiC.P., Ab'SaberA.M., ParraE.R., TakagakiT., PereiraJ.C., SoaresF.A., LeiteK., CapelozziV.L.: p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas.Braz J Med Biol Res, 40: 1045–1053, 2007.
27.
JeongS.H., LeeH.W., HanJ.H., KangS.Y., ChoiJ.H., JungY.M., ChoiH., OhY.T., ParkK.J., HwangSCh, SheenS.S., OhY.J., KimJ.H., LimH.Y.: Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology.Jpn J Clin Oncol, 38: 661–669, 2008.
28.
KondouM., NagayasuT., HidakaS., TsuchiyaT., TakeshitaH., YasutakeT., YanoH., MinamiH., IwasakiK.: Correlation between angiogenesis and p53 expression in lung adenocarcinoma of young patients.Tohoku J Exp Med, 217: 101–107, 2009.
29.
SinghalS., VachaniA., Antin-OzerkisD., KaiserL.R., AlbeldaS.M.: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.Clin Cancer Res, 11: 3974–3986, 2005.
30.
ZhuC.Q., ShihW., LingC.H., TsaoM.S.: Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.J Clin Pathol, 59: 790–800, 2006.
31.
SteelsE., PaesmansM., BerghmansT.: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.Eur Respir J, 18: 705–719, 2001.
32.
GroegerA.M., EspositoV., De LucaA., CassandroR., ToniniG., AmbrogiV., MineoT.C., PersichettiP., LiuzziG., MontesarchioV., WolnerE., BaldiF., GroegerA.M.: Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers.Histopathology, 44: 54–63, 2004.
33.
GiachinoD., GhioP., RegazzoniS., MandrileG., NovelloS., SelvaggiG., GregoriD., DeMarchiM., ScagliottiG.: Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.Clin Cancer Res, 13: 2876–81, 2007.
34.
HouS.M., RykC., KannioA., AngeliniS., FältS., NybergF., Husgafvel-PursiainenK.: Influence of common XPD and XR-CC1 variant alleles on p53 mutations in lung tumors.Environ Mol Mutagen, 41: 37–42, 2003.
35.
ChangH.K., BoG.J., Dong-WanK., DooHCh, YoungT.K., SanghoonJ., Sook-WhanS., JooH.K.: The prognostic significance of ERCC1, BRCA1, XRCC1, and III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.Lung Cancer, 68(3): 478–483, 2010. E pub 2009 Aug 15.
36.
KangC.H., JangB.G., KimD.W., ChungD.H., KimY.T., JheonS., SungS.W., KimJ.H.: Differences in the expression profiles of excision repair cross-complementation group 1, X-ray repair cross-complementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival.J Thorac Oncol, 4: 1307–1312, 2009.
37.
FujiiT., ToyookaS., IchimuraK., FujiwaraY., HottaK., SohJ., SuehisaH., KobayashiN., AoeM., YoshinoT., KiuraK., DateH.: ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.Lung Cancer, 59: 377–384, 2008.
38.
de las PeñasR., Sanchez-RoncoM., AlberolaV., TaronM., CampsC., Garcia-CarboneroR., MassutiB., QueraltC., BotiaM., Garcia-GomezR., IslaD., CoboM., SantarpiaM., CecereF., MendezP., SanchezJ.J., RosellR.: Spanish Lung Cancer Group. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.Ann Oncol, 17: 668–675, 2006.
39.
WangZ.H., MiaoX.P., TanW., ZhangX.R., XuB.H., LinD.X.: Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer.Ai Zheng, 23: 865–868, 2004.
